There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary therapies, and medication.

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

At 77 years old, Tyson Johnson has been in treatment for metastatic prostate cancer for more than 20 years. “I’m the healthiest dead man you’ve ever seen,” the Carthage resident said jokingly as he ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

Check The Box! kicked off on the court at the Naismith Memorial Basketball Hall of Fame as well as during the 2026 Panini Hoophall Classic in January. This is a five-year commitment between the ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

They use the body's own immune system to detect and kill cancer cells "Immunotherapies have been very promising and has ...

A new study provides hope that smarter timing of cancer treatments could improve cure rates. The study's Principal Investigator, Dr Robert Noble, Senior Lecturer at the Department of Mathematics, City ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.